Kronos Bio, Inc.
KRON
Price:
$0.9291
Market Cap:
$56.02M
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 ...[Read more]
Industry
Biotechnology
IPO Date
2020-10-09
Stock Exchange
NASDAQ
Ticker
KRON
The ROE as of September 2024 (TTM) for Kronos Bio, Inc. (KRON) is -68.82%
According to Kronos Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -68.82%. This represents a change of 301.81% compared to the average of -17.13% of the last 4 quarters.
Kronos Bio, Inc. (KRON) Historical ROE (quarterly & annually)
How has KRON ROE performed in the past?
The mean historical ROE of Kronos Bio, Inc. over the last ten years is -3.69%. The current -68.82% ROE has changed 1.77% with respect to the historical average. Over the past ten years (40 quarters), KRON's ROE was at its highest in in the September 2020 quarter at 52.06%. The ROE was at its lowest in in the March 2019 quarter at -31.06%.
Average
-3.69%
Median
-28.49%
Minimum
-70.83%
Maximum
92.12%
Kronos Bio, Inc. (KRON) ROE by Quarter and Year
Discovering the peaks and valleys of Kronos Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 213.84%
Maximum Annual ROE = 92.12%
Minimum Annual Increase = -120.72%
Minimum Annual ROE = -70.83%
| Year | ROE | Change |
|---|---|---|
| 2023 | -70.83% | 33.94% |
| 2022 | -52.88% | 22.39% |
| 2021 | -43.21% | 213.84% |
| 2020 | -13.77% | -120.72% |
| 2019 | 66.45% | -27.87% |
Kronos Bio, Inc. (KRON) Average ROE
How has KRON ROE performed in the past?
The current ROE of Kronos Bio, Inc. (KRON) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-55.64%
5-year avg
-22.85%
10-year avg
-3.69%
Kronos Bio, Inc. (KRON) ROE vs. Peers
How is KRON’s ROE compared to its peers?
Kronos Bio, Inc.’s ROE is less than Cyclerion Therapeutics, Inc. (28.07%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Addex Therapeutics Ltd (-456.73%), greater than Achilles Therapeutics plc (-47.36%), greater than NextCure, Inc. (-57.63%), greater than CytomX Therapeutics, Inc. (-27.44%), greater than Neoleukin Therapeutics, Inc. (-47.64%), less than Spero Therapeutics, Inc. (20.70%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Replimune Group, Inc. (-52.15%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Gossamer Bio, Inc. (-117.33%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), less than Inhibrx, Inc. (1.62%), greater than Merus N.V. (-36.33%), greater than Lyell Immunopharma, Inc. (-33.35%), greater than Generation Bio Co. (-92.86%), greater than Erasca, Inc. (-131.94%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Edgewise Therapeutics, Inc. (-28.01%),
| Company | ROE | Market cap |
|---|---|---|
| 28.07% | $7.86M | |
| -37.84% | $426.23M | |
| -456.73% | $15.98M | |
| -47.36% | $28.99M | |
| -57.63% | $36.09M | |
| -27.44% | $96.48M | |
| -47.64% | $8.20M | |
| 20.70% | $72.97M | |
| -121.55% | $113.14M | |
| -52.15% | $712.93M | |
| -152.26% | $117.02M | |
| -143.74% | $18.36M | |
| -117.33% | $207.43M | |
| -62.63% | $4.33B | |
| 1.62% | $255.93M | |
| -36.33% | $3.42B | |
| -33.35% | $311.04M | |
| -92.86% | $165.18M | |
| -131.94% | $786.77M | |
| -44.60% | $437.87M | |
| -28.01% | $1.59B |
Build a custom stock screener for Kronos Bio, Inc. (KRON) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kronos Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Kronos Bio, Inc. (KRON) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Kronos Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Kronos Bio, Inc.'s ROE?
How is the ROE calculated for Kronos Bio, Inc. (KRON)?
What is the highest ROE for Kronos Bio, Inc. (KRON)?
What is the 3-year average ROE for Kronos Bio, Inc. (KRON)?
What is the 5-year average ROE for Kronos Bio, Inc. (KRON)?
How does the current ROE for Kronos Bio, Inc. (KRON) compare to its historical average?